RefleXion is the first and only company to develop biology-guided radiotherapy (BgRT*), a novel treatment modality designed to use PET signals emitting from malignant lesions to guide, in real time, external-beam radiotherapy delivery. RefleXion aims to eventually treat all solid tumor types and of all cancer stages using BgRT by making external-beam radiotherapy more precise in ablating single or multiple malignant lesions. BgRT expands the use of PET tracers beyond disease diagnoses to create a new utility and new market improving radiotherapy delivery.
Initially developed for use with FDG, RefleXion is building a portfolio of PET tracers as real-time BgRT guides, including PSMA-targeted BgRT for patients with all stages of prostate cancer. RefleXion has signed collaboration agreements with both Telix Pharmaceuticals and Lantheus to develop their PSMA-targeted PET tracers for RefleXion’s X1 BgRT platform.
Visit us at booth 950 during SNMMI 2022 and for more information, visit www.reflexion.com or contact marketinginfo@reflexion.com.
Ad Statistics
Times Displayed: 2130
Times Visited: 4 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
*The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.
